Guggenheim Capital LLC decreased its position in Puma Biotechnology Inc (NASDAQ:PBYI) by 14.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 36,125 shares of the biopharmaceutical company’s stock after selling 6,324 shares during the quarter. Guggenheim Capital LLC owned about 0.10% of Puma Biotechnology worth $3,571,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in PBYI. Nationwide Fund Advisors grew its stake in shares of Puma Biotechnology by 22.5% in the 3rd quarter. Nationwide Fund Advisors now owns 19,879 shares of the biopharmaceutical company’s stock valued at $2,381,000 after buying an additional 3,657 shares in the last quarter. First Trust Advisors LP acquired a new stake in Puma Biotechnology in the 3rd quarter worth approximately $549,000. Sei Investments Co. acquired a new stake in Puma Biotechnology in the 3rd quarter worth approximately $256,000. New York State Common Retirement Fund lifted its holdings in Puma Biotechnology by 38.9% in the 3rd quarter. New York State Common Retirement Fund now owns 44,792 shares of the biopharmaceutical company’s stock worth $5,364,000 after purchasing an additional 12,545 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Puma Biotechnology by 33.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 182,298 shares of the biopharmaceutical company’s stock worth $21,832,000 after purchasing an additional 46,001 shares during the last quarter. 95.95% of the stock is owned by institutional investors and hedge funds.
In other news, SVP Richard Paul Bryce sold 1,860 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $172,515.00. Following the completion of the transaction, the senior vice president now directly owns 25,379 shares in the company, valued at $2,353,902.25. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alan H. Auerbach sold 10,692 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $991,683.00. Following the transaction, the insider now owns 4,155,931 shares of the company’s stock, valued at $385,462,600.25. The disclosure for this sale can be found here. 21.10% of the stock is owned by insiders.
Shares of PBYI stock opened at $62.80 on Friday. Puma Biotechnology Inc has a 12 month low of $28.35 and a 12 month high of $136.90. The company has a market cap of $2,508.36, a PE ratio of -8.00 and a beta of 0.15. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.82 and a quick ratio of 1.79.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) EPS for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.27. The business had revenue of $21.60 million for the quarter, compared to analyst estimates of $20.83 million. During the same quarter last year, the firm earned ($1.22) earnings per share. equities analysts anticipate that Puma Biotechnology Inc will post -4.07 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Guggenheim Capital LLC Sells 6,324 Shares of Puma Biotechnology Inc (PBYI)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3337477/guggenheim-capital-llc-sells-6324-shares-of-puma-biotechnology-inc-pbyi.html.
Puma Biotechnology Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.